Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers

Journal of Clinical Oncology

Volumn 27, Issue 23, 2009, Pages 3764-3771

  Kriege, Mieke ^a   Seynaeve, Caroline ^a   Meijers Heijboer, Hanne ^a   Collee, J Margriet ^a   Menke Pluymers, Marian B E ^a   Bartels, Carina C M ^a   Tilanus Linthorst, Madeleine M A ^a   Blom, Jannet ^a   Huijskens, Elisabeth ^a   Jager, Agnes ^a   Van Den Ouweland, Ans ^a   Van Geel, Bert ^a   Hooning, Maartje J ^a   Brekelmans, Cecile T M ^a   Klijn, Jan G M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAXANE DERIVATIVE; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BIRTH; BRCA2 GENE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; FEMALE; GENE MUTATION; HAZARD RATIO; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; AGED; ANALYSIS OF VARIANCE; BREAST TUMOR; CANCER STAGING; CHEMISTRY; DISEASE COURSE; DISEASE FREE SURVIVAL; GENETICS; HETEROZYGOTE; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MUTATION; PATHOLOGY;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HETEROZYGOTE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RESEARCH DESIGN;

EID: 68949127264     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.9067     Document Type: Article

References (39)

1. Peto J, Collins N, Barfoot R, et al: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943-949, 1999
2. Kennedy RD, Quinn JE, Mullan PB, et al: The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96:1659-1668, 2004
3. Foulkes WD: BRCA1 and BRCA2: Chemosensitivity, treatment outcomes and prognosis. Fam Cancer 5:135-142, 2006
4. James CR, Quinn JE, Mullan PB, et al: BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist 12:142-150, 2007
5. Robson ME: Treatment of hereditary breast cancer. Semin Oncol 34:384-391, 2007
6. Verhoog LC, Brekelmans CT, Seynaeve C, et al: Survival and tumour characteristics of breastcancer patients with germline mutations of BRCA1. Lancet 351:316-321, 1998
7. Verhoog LC, Brekelmans CT, Seynaeve C, et al: Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 17:3396-3402, 1999
8. Liebens FP, Carly B, Pastijn A, et al: Management of BRCA1/2 associated breast cancer: A systematic qualitative review of the state of knowledge in 2006. Eur J Cancer 43:238-257, 2007
9. Goffin JR, Chappuis PO, Begin LR, et al: Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer 97:527-536, 2003
10. Robson ME, Chappuis PO, Satagopan J, et al: A combined analysis of outcome following breast cancer: Differences in survival based on BRCA1/ BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8-R17, 2004
11. Rennert G, Bisland-Naggan S, Barnett-Griness O, et al: Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:115-123, 2007
12. Brekelmans CT, Seynaeve C, Menke-Pluymers M, et al: Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 17: 391-400, 2006
13. Chappuis PO, Goffin J, Wong N, et al: A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 39:608-610, 2002
14. Delaloge S, Pautier P, Kloos I, et al: BRCA1-linked breast cancer (BC) is highly more chemosensitive than its BRCA2-linked or sporadic counterparts. 27th Congress of the European Society for Medical Oncology, October 18-22, 2002, Nice, France (abstr 120)
15. Byrski T, Gronwald J, Huzarski T, et al: Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 108:289-296, 2008
16. Kurebayashi J, Yamamoto Y, Kurosumi M, et al: Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes. Anticancer Res 26:695-701, 2006
17. van der Hout AH, van den Ouweland AM, van der Luijt RB, et al: A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: Application in a Dutch cancer clinic setting. Hum Mutat 27:654-666, 2006
18. Hayward JL, Carbone PP, Heuson JC, et al: Assessment of response to therapy in advanced breast cancer: A project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer 39:1289-1294, 1977
19. Robson M, Offit K: Clinical practice: Management of an inherited predisposition to breast cancer. N Engl J Med 357:154-162, 2007
20. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al: International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122:2017-2022, 2008
21. Meijers-Heijboer H, van Geel B, Van Putten WL, et al: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159-164, 2001
22. Kriege M, Brekelmans CT, Boetes C, et al: Efficacy of MRI and mammography for breastcancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427-437, 2004
23. Foulkes WD, Goffin J, Brunet JS, et al: Tamoxifen may be an effective adjuvant treatment for BRCA1-related breast cancer irrespective of estrogen receptor status. J Natl Cancer Inst 94:1504-1506, 2002
24. Kriege M, Seynaeve C, Meijers-Heijboer H, et al: Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients. Breast Cancer Res Treat 111:303-311, 2008
25. Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281, 2008
26. Rakha EA, Reis-Filho JS, Ellis IO: Basal-like breast cancer: A critical review. J Clin Oncol 26: 2568-2581, 2008
27. Miyoshi Y, Murase K, Oh K: Basal-like subtype and BRCA1 dysfunction in breast cancers. Int J Clin Oncol 13:395-400, 2008
28. Byrski T, Huzarski T, Dent R, et al: Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 115:359-362, 2009
29. Cass I, Baldwin RL, Varkey T, et al: Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97:2187-2195, 2003
30. Tan DS, Rothermundt C, Thomas K, et al: "BRCAness" syndrome in ovarian cancer: A casecontrol study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26:5530-5536, 2008
31. Shanley S, McReynolds K, Ardern-Jones A, et al: Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. Clin Cancer Res 12:7033-7038, 2006
32. Tutt AN, Lord CJ, McCabe N, et al: Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 70:139-148, 2005
33. Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921, 2005
34. Bryant HE, Schultz N, Thomas HD, et al: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917, 2005
35. De Soto JA, Deng CX: PARP-1 inhibitors: Are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers? Int J Med Sci 3:117-123, 2006
36. Edwards SL, Brough R, Lord CJ, et al: Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451:1111-1115, 2008
37. Sakai W, Swisher EM, Karlan BY, et al: Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451:1116-1120, 2008
38. Swisher EM, Sakai W, Karlan BY, et al: Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 68:2581-2586, 2008
39. Li L, Wang H, Yang ES, et al: Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res 68:9141-9146, 2008